Supplemental Material
Published: 8 July 2023| Version 3 | DOI: 10.17632/jtz2cnyp4g.3
Contributors:
, , , , , , , , , , , , , , , Michael Chen, Description
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up
Files
Categories
Dermatology, Psoriasis